|
Szklarz, G D; Halpert, J R (1998) Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. Drug Metab Dispos 26:1179-84
|
|
Szklarz, G D; Halpert, J R (1997) Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. Life Sci 61:2507-20
|
|
Harlow, G R; He, Y A; Halpert, J R (1997) Functional interaction between amino-acid residues 242 and 290 in cytochromes P-450 2B1 and 2B11. Biochim Biophys Acta 1338:259-66
|
|
Liu, J; He, Y A; Halpert, J R (1996) Role of residue 480 in substrate specificity of cytochrome P450 2B5 and 2B11. Arch Biochem Biophys 327:167-73
|
|
Harlow, G R; Halpert, J R (1996) Mutagenesis study of Asp-290 in cytochrome P450 2B11 using a fusion protein with rat NADPH-cytochrome P450 reductase. Arch Biochem Biophys 326:85-92
|
|
Fang, X; Halpert, J R (1996) Dithionite-supported hydroxylation of palmitic acid by cytochrome P450BM-3. Drug Metab Dispos 24:1282-5
|
|
Born, S L; John, G H; Harlow, G R et al. (1995) Characterization of the progesterone 21-hydroxylase activity of canine cytochrome P450 PBD-2/P450 2B11 through reconstitution, heterologous expression, and site-directed mutagenesis. Drug Metab Dispos 23:702-7
|
|
Klekotka, P A; Halpert, J R (1995) Benzyloxyresorufin as a specific substrate for the major phenobarbital-inducible dog liver cytochrome P450 (P4502B11). Drug Metab Dispos 23:1434-5
|
|
John, G H; Hasler, J A; He, Y A et al. (1994) Escherichia coli expression and characterization of cytochromes P450 2B11, 2B1, and 2B5. Arch Biochem Biophys 314:367-75
|
|
Hasler, J A; Harlow, G R; Szklarz, G D et al. (1994) Site-directed mutagenesis of putative substrate recognition sites in cytochrome P450 2B11: importance of amino acid residues 114, 290, and 363 for substrate specificity. Mol Pharmacol 46:338-45
|
Showing the most recent 10 out of 16 publications
